Oct 2026 $54 M No. 5 $50 to $250 million 18
Ansa Biotechnologies, Inc.: Raise no. 5, Oct 2026 × Investors in this round 18 investors had bought by the notice of Nov 18, 2026: 18 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $54 M of $72 M offered; $18 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Daniel Lin-Arlow · Executive Officer, Director Geoff Hamilton · Executive Officer Jason T Gammack · Executive Officer, Director Matthias Arenskotter · Executive Officer Sebastian Palluk · Executive Officer Brad Crutchfield · Director Chenny Zhang · Director Nate Cornell · Director Nick Naclerio · Director Yanniv Dorone · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Jason T. Gammack, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 18, 2026. Read the notice at the SEC .
equity SEC Jun 2024 $46 M No. 4 $10 to $50 million 41
Ansa Biotechnologies, Inc.: Raise no. 4, Jun 2024 × Investors in this round 41 investors had bought by the notice of Dec 10, 2025: 41 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $46 M of $57 M offered; $10 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Daniel T. Lin-Arlow · Executive Officer, Director Jason T. Gammack · Executive Officer, Director Sebastian T. Palluk · Executive Officer Chenny T. Zhang · Director Matthew T. McManus · Director Yanniv T. Dorone · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Jason T. Gammack, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Dec 10, 2025. Read the notice at the SEC .
equity SEC Mar 2022 $68 M No. 3 $50 to $250 million 28
Ansa Biotechnologies, Inc.: Raise no. 3, Mar 2022 × Investors in this round 28 investors had bought by the notice of May 5, 2022: 28 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $68 M of $77 M offered; $9 M still to sell
Smallest investment taken no minimum stated
What was sold equity, debt Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Daniel Lin-Arlow · Executive Officer, Director Sebastian Palluk · Executive Officer, Director Lily Li · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Daniel Lin-Arlow, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed May 5, 2022. Read the notice at the SEC .
equity, debt SEC Oct 2021 $5 M No. 2 $2 to $10 million 7
Ansa Biotechnologies, Inc.: Raise no. 2, Oct 2021 × Investors in this round 7 investors had bought by the notice of Oct 15, 2021: 7 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $5 M offered
Smallest investment taken no minimum stated
What was sold equity, debt Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Daniel Lin-Arlow · Executive Officer, Director Sebastian Palluk · Executive Officer, Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Daniel Lin-Arlow, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 15, 2021. Read the notice at the SEC .
equity, debt SEC Jun 2020 $5 M No. 1 $2 to $10 million 24
Ansa Biotechnologies, Inc.: Raise no. 1, Jun 2020 × Investors in this round 24 investors had bought by the notice of Jul 9, 2020: 24 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $9 M offered; $4 M still to sell
Smallest investment taken no minimum stated
What was sold equity, debt, other: "Series Seed-1 Pfd Stock, Series Seed-2 Prd Stock, Series Seed-3 Pfd Stock, Series Seed-4 Pfd Stock, Series Seed-5 Pfd Stock, and Simple Agreements for Future Equity (""SAFES"") and the underlying sha Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and finders' fees and payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Daniel Hillel Lin-Arlow · Executive Officer, Director Sebastian Hillel Palluk · Executive Officer, Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Daniel Hillel Lin-Arlow, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 9, 2020. Read the notice at the SEC .
equity, debt SEC